PortfoliosLab logoPortfoliosLab logo
MDCX vs. LLY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

MDCX vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Medicus Pharma Ltd (MDCX) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, MDCX achieves a -70.65% return, which is significantly lower than LLY's 2.90% return.


MDCX

1D
-1.86%
1M
49.67%
YTD
-70.65%
6M
-71.22%
1Y
-81.97%
3Y*
5Y*
10Y*

LLY

1D
0.32%
1M
3.48%
YTD
2.90%
6M
2.73%
1Y
45.51%
3Y*
34.88%
5Y*
39.70%
10Y*
33.08%
*Multi-year figures are annualized to reflect compound growth (CAGR)

MDCX vs. LLY - Yearly Performance Comparison


2026 (YTD)20252024
MDCX
Medicus Pharma Ltd
-70.65%-37.04%-21.61%
LLY
Eli Lilly and Company
2.90%40.25%-4.75%

Correlation

The correlation between MDCX and LLY is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.09

Correlation (All Time)
Calculated using the full available price history since Nov 14, 2024

0.05

Fundamentals

EPS

MDCX:

-$1.93

LLY:

$28.14

Total Revenue (TTM)

MDCX:

$0.00

LLY:

$72.25B

Gross Profit (TTM)

MDCX:

$0.00

LLY:

$59.75B

EBITDA (TTM)

MDCX:

-$36.18M

LLY:

$32.97B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MDCX vs. LLY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MDCX
MDCX Risk / Return Rank: 1212
Overall Rank
MDCX Sharpe Ratio Rank: 1414
Sharpe Ratio Rank
MDCX Sortino Ratio Rank: 1414
Sortino Ratio Rank
MDCX Omega Ratio Rank: 1414
Omega Ratio Rank
MDCX Calmar Ratio Rank: 77
Calmar Ratio Rank
MDCX Martin Ratio Rank: 99
Martin Ratio Rank

LLY
LLY Risk / Return Rank: 7575
Overall Rank
LLY Sharpe Ratio Rank: 7777
Sharpe Ratio Rank
LLY Sortino Ratio Rank: 7272
Sortino Ratio Rank
LLY Omega Ratio Rank: 7474
Omega Ratio Rank
LLY Calmar Ratio Rank: 7575
Calmar Ratio Rank
LLY Martin Ratio Rank: 7676
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MDCX vs. LLY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Medicus Pharma Ltd (MDCX) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


MDCXLLYDifference
Sharpe ratioReturn per unit of total volatility

-1.86

Sortino ratioReturn per unit of downside risk

-2.65

Omega ratioGain probability vs. loss probability

0.88

1.24

-0.36

Calmar ratioReturn relative to maximum drawdown

-0.89

1.97

-2.87

Martin ratioReturn relative to average drawdown

-1.37

4.93

-6.30

MDCX vs. LLY - Sharpe Ratio Comparison

The current MDCX Sharpe Ratio is -0.65, which is lower than the LLY Sharpe Ratio of 1.21. The chart below compares the historical Sharpe Ratios of MDCX and LLY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

MDCX vs. LLY - Drawdown Comparison

The maximum MDCX drawdown since its inception was -96.47%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for MDCX and LLY.


Loading charts...

Drawdown Indicators


MDCXLLYDifference

Max Drawdown

Largest peak-to-trough decline

-96.47%

-68.24%

-28.23%

Max Drawdown (1Y)

Largest decline over 1 year

-91.91%

-23.18%

-68.73%

Max Drawdown (3Y)

Largest decline over 3 years

-34.48%

Max Drawdown (5Y)

Largest decline over 5 years

-34.48%

Max Drawdown (10Y)

Largest decline over 10 years

-34.48%

Current Drawdown

Current decline from peak

-94.23%

-5.07%

-89.16%

Average Drawdown

Average peak-to-trough decline

-57.66%

-19.20%

-38.46%

Ulcer Index

Depth and duration of drawdowns from previous peaks

59.85%

9.26%

+50.59%

Volatility

MDCX vs. LLY - Volatility Comparison

Medicus Pharma Ltd (MDCX) has a higher volatility of 35.89% compared to Eli Lilly and Company (LLY) at 8.76%. This indicates that MDCX's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


MDCXLLYDifference

Volatility (1M)

Calculated over the trailing 1-month period

35.89%

8.76%

+27.13%

Volatility (6M)

Calculated over the trailing 6-month period

119.19%

26.89%

+92.30%

Volatility (1Y)

Calculated over the trailing 1-year period

126.68%

37.90%

+88.78%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

131.88%

32.46%

+99.42%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

131.88%

30.20%

+101.68%

Dividends

MDCX vs. LLY - Dividend Comparison

MDCX has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.59%.


PositionTTM20252024202320222021202020192018201720162015
LLY
Eli Lilly and Company
0.59%0.56%0.67%0.78%1.07%1.23%1.75%1.96%1.94%2.46%2.77%2.37%
MDCX
Medicus Pharma Ltd
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

MDCX vs. LLY - Financials Comparison

This section allows you to compare key financial metrics between Medicus Pharma Ltd and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20.00BJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober20260
19.80B
(MDCX) Total Revenue
(LLY) Total Revenue
Values in USD except per share items

Frequently Asked Questions


MDCX and LLY have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MDCX has higher volatility (35.89%) compared to LLY (8.76%). In terms of maximum drawdown, MDCX dropped -96.47% vs LLY's -68.24%.

LLY currently has the higher Sharpe Ratio (1.21 vs -0.65), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for MDCX and LLY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer